We are finally getting what we asked for: Pharma is ponying up for head to head studies to provide us with meaningful data to help make better clinical decisions. However, these valuable projects are often with systemic agents, such as biologics, leaving topical treatments in the dust.
To address this, Dr. Lawrence Eichenfield, Professor of Dermatology and Pediatrics, UCSD, and colleagues sought to make the most out of the data we do have on the litany of topical options for atopic dermatitis and provide efficacy and safety guidance (A for effort!).
Tune in to hear what this dream team concocted about creams. Hear how an expert approaches new atopic dermatitis patients. Don’t miss out – this is all very topical.
Listen Now
You May Also Like
The PASI Paradigm Shift: How Higher Clinical Trial Endpoints Are Reshaping Dermatology
The PASI Paradigm Shift: How Higher Clinical Trial Endpoints Are Reshaping Dermatology
Remember when PASI 75 was the gold medal? Today, it barely makes the podium. In this episode of the JDD Podcast, host Dr. Adam Friedman welcomes Dr. James Song for…
(P)Steroids & the Psyche: The Problems Nobody Put on the Prescription Label
(P)Steroids & the Psyche: The Problems Nobody Put on the Prescription Label
Guest: Dr. Lucinda Whitney When corticosteroid risks come up, most clinicians immediately think about osteoporosis, hyperglycemia, infection risk, or adrenal suppression. But what about the organ sitting between the ears?…
From Endpoint to Exam Room: Understanding What Psoriasis Trials Really Tell Us
From Endpoint to Exam Room: Understanding What Psoriasis Trials Really Tell Us
Guest: Dr. Andrew Blauvelt Not all psoriasis data tell the same story, and sometimes the loudest signal isn't the most important one. In this episode of the JDD Podcast, host…
